Magic mushroom compound tested for stubborn bipolar depression

NCT ID NCT06943573

Not yet recruiting Symptom relief Sponsor: Lakshmi N Yatham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single 25 mg dose of psilocybin, given with therapy, can ease depression in people with bipolar II disorder who haven't improved with standard treatments. About 90 adults aged 19-65 will receive either the full dose or a very low placebo dose, and their mood changes will be tracked over 12 weeks. The goal is to see if this approach is safe and effective for treatment-resistant symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR II DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar disorder bipolar II disorder Depression major depressive disorder mood disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR II DEPRESSION

Contacts and locations

Locations

Department of Psychiatry, University of Ottawa, The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada
Department of Psychiatry, University of Toronto, University Health Network,

Toronto, Ontario, M5T 2S8, Canada
Djavad Mowafaghian Centre for Brain Health

Vancouver, British Columbia, V6T 1Z3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.